N	Concordance
1	initial  studies of successful combined-modality therapy was fluorouracil (5-FU)
2	d were distributed as follows: combined-modality therapy (CMT), 55 patients; che
3	herapy that is not a part of a combined-modality therapy is counted as a regi
4	rospective study suggests that combined-modality therapy is preferable to single
5	-free survival. The benefit of combined-modality therapy over radiation therapy 
6	co consumption and  aggressive combined-modality treatment programs, both the in
7	S of less than 5%. Thus, using combined-modality treatment (chemotherapy, then m
8	d be particularly suitable for combined-modality treatment of prostate cancer. P